IVAC MUTANOME: A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma

被引：0
|
作者：
Miller, M. [1 ]
Sahin, U. [2 ]
Derhovanessian, E. [3 ]
Kloke, B-P. [1 ]
Simon, P. [4 ]
Bukur, V. [5 ]
Albrecht, C. [6 ]
Paruzynski, A. [5 ]
Loewer, M. [7 ]
Kuhn, A. [8 ]
Schreeb, K. [9 ]
Attig, S. [10 ]
Brueck, A. Kemmer [9 ]
Bolte, S. [9 ]
Grabbe, S. [11 ]
Hoeller, C. [12 ]
Utikal, J. [13 ]
Huber, C. [14 ]
Loquai, C. [11 ]
Tuereci, O. [15 ]
机构：
[1] Biopharmaceut New Technol BioNTech Corp, Project Management, Mainz, Germany
[2] Biopharmaceut New Technol BioNTech Corp, Management, Mainz, Germany
[3] Biopharmaceut New Technol BioNTech Corp, Immunomonitoring, Mainz, Germany
[4] Biopharmaceut New Technol BioNTech Corp, Immunoreceptor Validat, Mainz, Germany
[5] Biopharmaceut New Technol BioNTech Corp, Genom, Mainz, Germany
[6] Johannes Gutenberg Univ gGmbH, Univ Med Ctr, TRON Translat Oncol, Genom, Mainz, Germany
[7] Johannes Gutenberg Univ gGmbH, Univ Med Ctr, TRON Translat Oncol, Bioinformat, Mainz, Germany
[8] Biopharmaceut New Technol BioNTech Corp, RNA Biochem, Mainz, Germany
[9] Biopharmaceut New Technol BioNTech Corp, Clin Res, Mainz, Germany
[10] Johannes Gutenberg Univ gGmbH, Univ Med Ctr, TRON Translat Oncol, Immunmonitoring, Mainz, Germany
[11] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dermatol, Mainz, Germany
[12] Med Univ Vienna, Dermatol, Vienna, Austria
[13] German Canc Res Ctr, Dermatol, Heidelberg, Germany
[14] Biopharmaceut New Technol BioNTech Corp, Advisory Board, Mainz, Germany
[15] CI3 Cluster Individualized Immunointervent, Management, Mainz, Germany
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6O
引用
收藏
页数：2
相关论文
共 50 条
  • [41] An open-label, first-in-human, phase I trial of the safety and efficacy of daily PCLX-001.
    Sangha, Randeep S.
    Sehn, Laurie Helen
    Kuruvilla, John
    Weickert, Michael
    Mackey, John Robert
    Berthiaume, Luc G.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [42] The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial
    Schwenzer, Hagen
    De Zan, Erica
    Elshani, Mustafa
    van Stiphout, Ruud
    Kudsy, Mary
    Morris, Josephine
    Ferrari, Valentina
    Um, In Hwa
    Chettle, James
    Kazmi, Farasat
    Campo, Leticia
    Easton, Alistair
    Nijman, Sebastian
    Serpi, Michaela
    Symeonides, Stefan
    Plummer, Ruth
    Harrison, David J.
    Bond, Gareth
    Blagden, Sarah P.
    CLINICAL CANCER RESEARCH, 2021, 27 (23) : 6500 - 6513
  • [43] A first-in-human phase I trial with antibody drug conjugate ADCT-701 in neuroendocrine tumors and carcinomas
    Del Rivero, Jaydira
    Glod, John
    Magee, Tamika
    Cooper, Kimberley
    Rivero, Anna
    Lanfranconi, Tea
    Patel, Rashmika
    Figg, W. Douglas
    Pommier, Yves
    Widemann, Brigitte C.
    Roper, Nitin
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS672 - TPS672
  • [44] Volunteer feedback and perceptions after participation in a phase I, first-in-human Ebola vaccine trial: An anonymous survey
    Dayer, Julie-Anne
    Siegrist, Claire-Anne
    Huttner, Angela
    PLOS ONE, 2017, 12 (03):
  • [45] FIRST-IN-HUMAN PHASE I TRIAL OF IBI188, AN ANTI-CD47 TARGETING MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS AND LYMPHOMAS
    Lakhani, Nehal
    Orloff, Marlana
    Fu, Siqing
    Liu, Ying
    Wang, Yan
    Zhou, Hui
    Lin, Kedan
    Liu, Fang
    Yan, Shuling
    Patnaik, Amita
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A180 - A180
  • [46] First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors
    Cole, Christopher B.
    Morelli, Maria Pia
    Fantini, Massimo
    Miettinen, Markku
    Fetsch, Patricia
    Peer, Cody
    Figg, William D.
    Yin, Tyler
    Houston, Nicole
    McCoy, Ann
    Lipkowitz, Stanley
    Zimmer, Alexandra
    Lee, Jung-min
    Pavelova, Miroslava
    Villanueva, Erin N.
    Trewhitt, Kathryn
    Solarz, B. Brooke
    Fergusson, Maria
    Mavroukakis, Sharon A.
    Zaki, Anjum
    Tsang, Kwong Y.
    Arlen, Philip M.
    Annunziata, Christina M.
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2023, 42 (01)
  • [47] First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors
    Christopher B. Cole
    Maria Pia Morelli
    Massimo Fantini
    Markku Miettinen
    Patricia Fetsch
    Cody Peer
    William D. Figg
    Tyler Yin
    Nicole Houston
    Ann McCoy
    Stanley Lipkowitz
    Alexandra Zimmer
    Jung-min Lee
    Miroslava Pavelova
    Erin N. Villanueva
    Kathryn Trewhitt
    B. Brooke Solarz
    Maria Fergusson
    Sharon A. Mavroukakis
    Anjum Zaki
    Kwong Y. Tsang
    Philip M. Arlen
    Christina M. Annunziata
    Journal of Experimental & Clinical Cancer Research, 42
  • [48] Choice of Starting Dose for Molecularly Targeted Agents Evaluated in First-in-Human Phase I Cancer Clinical Trials
    Le Tourneau, Christophe
    Stathis, Anastasios
    Vidal, Laura
    Moore, Malcolm J.
    Siu, Lillian L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (08) : 1401 - 1407
  • [49] Immunological effects of checkpoint blockade plus galectin-3 inhibition with GR-MD-02 in a first-in-human phase I clinical trial
    Redmond, William
    Koguchi, Yoshinobu
    Fountain, Christopher d
    Traber, Peter
    Curti, Brendan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [50] A first-in-human phase I/IIa gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.GALGT2
    Flanigan, Kevin M.
    Vetter, Tatyana A.
    Simmons, Tabatha R.
    Iammarino, Megan
    Frair, Emma C.
    Rinaldi, Federica
    Chicoine, Louis G.
    Harris, Johan
    Cheatham, John P.
    Cheatham, Sharon L.
    Boe, Brian
    Waldrop, Megan A.
    Zygmunt, Deborah A.
    Packer, Davin
    Martin, Paul T.
    MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2022, 27 : 47 - 60
12345